Cystic Fibrosis Ireland is pleased to share that ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) is available for reimbursement from today - 1st September 2025.

Having remained in contact with Vertex throughout the Access to Medications campaign, CFI and the Access to Medications working group received the following statement from Vertex this morning;

“Vertex is pleased to confirm that the Corporate Pharmaceutical Unit (CPU) has confirmed reimbursement in Ireland for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) will be effective from September 1st, 2025. This follows the European Commission granting approval for ALYFTREK® for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in July 2025.” 

Emma Wallace, Senior Advocacy Coordinator, commented, “Together with the Access to Medication working group, we have campaigned tirelessly for these extensions, and this is such an important achievement for the CF population in Ireland.

"This marks the next major milestone in our fight to make sure every person with CF has the care and support they need and deserve.”

To read the Vertex press release issued in July, click here..